[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$faJetUO6YRtPHxVtylxBaFpAxvTNfchCi4xZE0CRYcVk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":84,"rows":91},"University of South Florida",[4],327,false,62,28,138846,18,231,[14,17,20,22,25,27,29,32],{"name":15,"count":16},"Depression",10,{"name":18,"count":19},"Generalized Anxiety Disorder",9,{"name":21,"count":19},"Obsessive-compulsive Disorder",{"name":23,"count":24},"Breast Cancer",7,{"name":26,"count":24},"Social Phobia",{"name":28,"count":24},"Separation Anxiety Disorder",{"name":30,"count":31},"Multiple Sclerosis",6,{"name":33,"count":31},"Anxiety",[35,40,45,50,54,59,64,69,74,79],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT03215862","Lactated Ringer's Solution to Prevent Post-ERCP Pancreatitis","2018-08-01","Lactated Ringer",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT02932007","Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study","2020-03","Chloroquine Phosphate",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT03739021","Exparel for Total Shoulder Pain","2020-03-01","Exparel",{"nctId":51,"briefTitle":52,"date":48,"intervention":53},"NCT04096144","Comparison of Sugammadex and Neostigmine During PACU Stay","Neuromuscular Blocking Agents",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT04305743","Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A","2021-01-01","OnabotulinumtoxinA 100 UNT",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04430179","Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis","2025-07","Dupilumab 300 MG\u002F2 ML Subcutaneous Solution [DUPIXENT]",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06577493","Effectiveness of Phenazopyridine for Pain Following Urodynamics","2025-11-24","Phenazopyridine Hydrochloride 99.5 MG",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT01933724","The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach","2025-12-31","5 mg prednisone",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT06887673","Lipid Mediators & Cancer: Montelukast, SPM, and Almonds","2026-03","Montelukast 10 Mg Oral",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT02630121","Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea","2026-04","Oxymetazoline Hydrochloride",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,122,145,172,206,229,250,274,292,320,338,369,394,415,437,463,481,503,521,558,591,618,636,663,681,710,728,750,775,793,818,836,854,879,905,931,949,972,998,1016,1042,1060,1087,1105,1129,1182,1214,1249,1275,1299,1326,1344,1370,1388,1413,1440,1458,1483,1509,1534,1557,1584,1602,1629,1647,1670,1697,1722,1760,1786,1812,1830,1854,1880,1898,1924,1948,1972,1990,2015,2038,2061,2085,2103,2129,2147,2165,2183,2205,2227,2252,2270,2295,2313,2336,2360,2386,2408,2443,2467,2490,2514,2538,2561,2588,2606,2630,2655,2679,2703,2721,2742,2767,2785,2815,2840,2862,2888,2911],{"intervention":58,"totalTrials":93,"cells":94},1,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":120},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":97},[],{"trials":105,"activeCount":93,"soonestReadout":57},[106],{"nctId":55,"briefTitle":56,"status":107,"phases":108,"primaryCompletion":57,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":119},"RECRUITING",[89],"2021-06-01","2019-10-09",60,[113,114,115,116,117,118],"Urinary Bladder, Overactive","Incontinence, Urge","Incontinence, Urinary","Urinary Urge Incontinence","Urinary Frequency More Than Once at Night","Nocturia",[58],{"trials":121,"activeCount":97},[],{"intervention":68,"totalTrials":93,"cells":123},{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":130,"PHASE4":132,"NA":143},{"trials":125,"activeCount":97},[],{"trials":127,"activeCount":97},[],{"trials":129,"activeCount":97},[],{"trials":131,"activeCount":97},[],{"trials":133,"activeCount":93,"soonestReadout":67},[134],{"nctId":65,"briefTitle":66,"status":135,"phases":136,"primaryCompletion":67,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":142},"ACTIVE_NOT_RECRUITING",[89],"2026-07-01","2024-12-17",66,[141],"Pain After Urodynamic Testing",[68],{"trials":144,"activeCount":97},[],{"intervention":146,"totalTrials":93,"cells":147},"Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period.",{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":170},{"trials":149,"activeCount":97},[],{"trials":151,"activeCount":97},[],{"trials":153,"activeCount":97},[],{"trials":155,"activeCount":97},[],{"trials":157,"activeCount":93,"soonestReadout":162},[158],{"nctId":159,"briefTitle":160,"status":107,"phases":161,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":169},"NCT07502378","Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency",[89],"2027-03-31","2027-08-31","2026-03-27",50,[167,168],"Ocular Surface Disease","Neurotrophic Keratopathy Stage 1",[146],{"trials":171,"activeCount":97},[],{"intervention":83,"totalTrials":173,"cells":174},2,{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":193},{"trials":176,"activeCount":97},[],{"trials":178,"activeCount":97},[],{"trials":180,"activeCount":97},[],{"trials":182,"activeCount":97},[],{"trials":184,"activeCount":93,"soonestReadout":82},[185],{"nctId":80,"briefTitle":81,"status":107,"phases":186,"primaryCompletion":82,"completion":82,"start":187,"enrollment":188,"conditions":189,"interventions":192},[89],"2023-04-01",52,[190,191],"Sleep Apnea","Chronic Nasal Congestion",[83],{"trials":194,"activeCount":97},[195],{"nctId":196,"briefTitle":197,"status":198,"phases":199,"primaryCompletion":200,"completion":200,"start":201,"enrollment":202,"conditions":203,"interventions":205},"NCT00584662","Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion","TERMINATED",[90],"2010-03","2005-01",42,[204],"Chronic Rhinitis",[83],{"intervention":49,"totalTrials":93,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":225,"NA":227},{"trials":209,"activeCount":97},[],{"trials":211,"activeCount":97},[],{"trials":213,"activeCount":97},[],{"trials":215,"activeCount":93,"soonestReadout":48},[216],{"nctId":46,"briefTitle":47,"status":217,"phases":218,"primaryCompletion":48,"completion":219,"start":220,"enrollment":111,"conditions":221,"interventions":223},"NOT_YET_RECRUITING",[87,88],"2020-11-15","2019-11",[222],"Chronic Shoulder Pain",[49,224],"Ropivacaine",{"trials":226,"activeCount":97},[],{"trials":228,"activeCount":97},[],{"intervention":53,"totalTrials":93,"cells":230},{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":246,"NA":248},{"trials":232,"activeCount":97},[],{"trials":234,"activeCount":97},[],{"trials":236,"activeCount":97},[],{"trials":238,"activeCount":93,"soonestReadout":48},[239],{"nctId":51,"briefTitle":52,"status":217,"phases":240,"primaryCompletion":48,"completion":241,"start":242,"enrollment":165,"conditions":243,"interventions":245},[88],"2020-06-15","2019-10-15",[244],"Neuromuscular Blockade",[53],{"trials":247,"activeCount":97},[],{"trials":249,"activeCount":97},[],{"intervention":73,"totalTrials":93,"cells":251},{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":258,"PHASE4":270,"NA":272},{"trials":253,"activeCount":97},[],{"trials":255,"activeCount":97},[],{"trials":257,"activeCount":97},[],{"trials":259,"activeCount":93,"soonestReadout":72},[260],{"nctId":70,"briefTitle":71,"status":135,"phases":261,"primaryCompletion":72,"completion":72,"start":262,"enrollment":263,"conditions":264,"interventions":268},[88],"2014-02-17",12,[265,266,267],"Granulomatosis With Polyangiitis","Wegener Granulomatosis","Vasculitis",[73,269],"0 mg prednisone",{"trials":271,"activeCount":97},[],{"trials":273,"activeCount":97},[],{"intervention":269,"totalTrials":93,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":288,"NA":290},{"trials":277,"activeCount":97},[],{"trials":279,"activeCount":97},[],{"trials":281,"activeCount":97},[],{"trials":283,"activeCount":93,"soonestReadout":72},[284],{"nctId":70,"briefTitle":71,"status":135,"phases":285,"primaryCompletion":72,"completion":72,"start":262,"enrollment":263,"conditions":286,"interventions":287},[88],[265,266,267],[73,269],{"trials":289,"activeCount":97},[],{"trials":291,"activeCount":97},[],{"intervention":293,"totalTrials":93,"cells":294},"Oxygen 99.7 %",{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":301,"PHASE4":316,"NA":318},{"trials":296,"activeCount":97},[],{"trials":298,"activeCount":97},[],{"trials":300,"activeCount":97},[],{"trials":302,"activeCount":93,"soonestReadout":307},[303],{"nctId":304,"briefTitle":305,"status":107,"phases":306,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":311,"interventions":314},"NCT06581003","Hyperbaric Oxygen Treatment for Veterans With Traumatic Brain Injury",[88],"2028-08-15","2029-08-15","2024-09-18",420,[312,313],"Traumatic Brain Injury","Military Operations",[293,315],"Oxygen 21 %",{"trials":317,"activeCount":97},[],{"trials":319,"activeCount":97},[],{"intervention":315,"totalTrials":93,"cells":321},{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":328,"PHASE4":334,"NA":336},{"trials":323,"activeCount":97},[],{"trials":325,"activeCount":97},[],{"trials":327,"activeCount":97},[],{"trials":329,"activeCount":93,"soonestReadout":307},[330],{"nctId":304,"briefTitle":305,"status":107,"phases":331,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":332,"interventions":333},[88],[312,313],[293,315],{"trials":335,"activeCount":97},[],{"trials":337,"activeCount":97},[],{"intervention":224,"totalTrials":173,"cells":339},{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":352,"NA":354},{"trials":341,"activeCount":97},[],{"trials":343,"activeCount":97},[],{"trials":345,"activeCount":97},[],{"trials":347,"activeCount":93,"soonestReadout":48},[348],{"nctId":46,"briefTitle":47,"status":217,"phases":349,"primaryCompletion":48,"completion":219,"start":220,"enrollment":111,"conditions":350,"interventions":351},[87,88],[222],[49,224],{"trials":353,"activeCount":97},[],{"trials":355,"activeCount":97},[356],{"nctId":357,"briefTitle":358,"status":359,"phases":360,"primaryCompletion":361,"completion":362,"start":363,"enrollment":111,"conditions":364,"interventions":367},"NCT01620047","Postoperative Knee Strength Following Total Knee Replacement: A Double-Blinded Randomized Comparison Study","COMPLETED",[90],"2012-01","2012-03","2011-03",[365,366],"Total Knee Replacement","Primary Knee Arthroplasty",[368,224,368],"Fentanyl",{"intervention":370,"totalTrials":93,"cells":371},"Efgartigimod",{"EARLY_PHASE1":372,"PHASE1":374,"PHASE2":376,"PHASE3":388,"PHASE4":390,"NA":392},{"trials":373,"activeCount":97},[],{"trials":375,"activeCount":97},[],{"trials":377,"activeCount":93,"soonestReadout":382},[378],{"nctId":379,"briefTitle":380,"status":217,"phases":381,"primaryCompletion":382,"completion":383,"start":384,"enrollment":16,"conditions":385,"interventions":387},"NCT06528392","Efgartigimod for Stiff Person Syndrome (ESPS)",[87],"2026-12-31","2027-12-31","2025-04-01",[386],"Stiff-Person Syndrome",[370],{"trials":389,"activeCount":97},[],{"trials":391,"activeCount":97},[],{"trials":393,"activeCount":97},[],{"intervention":63,"totalTrials":93,"cells":395},{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":409,"PHASE4":411,"NA":413},{"trials":397,"activeCount":97},[],{"trials":399,"activeCount":97},[],{"trials":401,"activeCount":93,"soonestReadout":62},[402],{"nctId":60,"briefTitle":61,"status":135,"phases":403,"primaryCompletion":62,"completion":62,"start":404,"enrollment":405,"conditions":406,"interventions":408},[87],"2020-12-17",30,[407],"Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis",[63],{"trials":410,"activeCount":97},[],{"trials":412,"activeCount":97},[],{"trials":414,"activeCount":97},[],{"intervention":44,"totalTrials":93,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":431,"PHASE4":433,"NA":435},{"trials":418,"activeCount":97},[],{"trials":420,"activeCount":97},[],{"trials":422,"activeCount":93,"soonestReadout":43},[423],{"nctId":41,"briefTitle":42,"status":107,"phases":424,"primaryCompletion":43,"completion":425,"start":426,"enrollment":427,"conditions":428,"interventions":430},[87],"2020-09","2017-03-28",40,[429],"Atrial Fibrillation",[44],{"trials":432,"activeCount":97},[],{"trials":434,"activeCount":97},[],{"trials":436,"activeCount":97},[],{"intervention":78,"totalTrials":93,"cells":438},{"EARLY_PHASE1":439,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":459,"NA":461},{"trials":440,"activeCount":93,"soonestReadout":77},[441],{"nctId":75,"briefTitle":76,"status":217,"phases":442,"primaryCompletion":77,"completion":77,"start":443,"enrollment":444,"conditions":445,"interventions":451},[85],"2025-03",56,[446,447,448,449,450],"Colorectal Cancer","Sarcoma","Brain Tumors","Endometrial Cancer","Ovarian Cancer",[78,452],"Montelukast 10 Mg Oral Tablet and SPM 4 g",{"trials":454,"activeCount":97},[],{"trials":456,"activeCount":97},[],{"trials":458,"activeCount":97},[],{"trials":460,"activeCount":97},[],{"trials":462,"activeCount":97},[],{"intervention":452,"totalTrials":93,"cells":464},{"EARLY_PHASE1":465,"PHASE1":471,"PHASE2":473,"PHASE3":475,"PHASE4":477,"NA":479},{"trials":466,"activeCount":93,"soonestReadout":77},[467],{"nctId":75,"briefTitle":76,"status":217,"phases":468,"primaryCompletion":77,"completion":77,"start":443,"enrollment":444,"conditions":469,"interventions":470},[85],[446,447,448,449,450],[78,452],{"trials":472,"activeCount":97},[],{"trials":474,"activeCount":97},[],{"trials":476,"activeCount":97},[],{"trials":478,"activeCount":97},[],{"trials":480,"activeCount":97},[],{"intervention":39,"totalTrials":93,"cells":482},{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":489,"PHASE4":491,"NA":493},{"trials":484,"activeCount":97},[],{"trials":486,"activeCount":97},[],{"trials":488,"activeCount":97},[],{"trials":490,"activeCount":97},[],{"trials":492,"activeCount":97},[],{"trials":494,"activeCount":93,"soonestReadout":38},[495],{"nctId":36,"briefTitle":37,"status":217,"phases":496,"primaryCompletion":38,"completion":38,"start":497,"enrollment":498,"conditions":499,"interventions":501},[90],"2017-08-01",242,[500],"Post-ERCP Acute Pancreatitis",[39,502],"Normal Saline 0.9% Infusion Solution Bag",{"intervention":502,"totalTrials":93,"cells":504},{"EARLY_PHASE1":505,"PHASE1":507,"PHASE2":509,"PHASE3":511,"PHASE4":513,"NA":515},{"trials":506,"activeCount":97},[],{"trials":508,"activeCount":97},[],{"trials":510,"activeCount":97},[],{"trials":512,"activeCount":97},[],{"trials":514,"activeCount":97},[],{"trials":516,"activeCount":93,"soonestReadout":38},[517],{"nctId":36,"briefTitle":37,"status":217,"phases":518,"primaryCompletion":38,"completion":38,"start":497,"enrollment":498,"conditions":519,"interventions":520},[90],[500],[39,502],{"intervention":522,"totalTrials":173,"cells":523},"solifenacin succinate",{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":530,"PHASE4":532,"NA":556},{"trials":525,"activeCount":97},[],{"trials":527,"activeCount":97},[],{"trials":529,"activeCount":97},[],{"trials":531,"activeCount":97},[],{"trials":533,"activeCount":97},[534,544],{"nctId":535,"briefTitle":536,"status":359,"phases":537,"primaryCompletion":538,"completion":538,"start":539,"enrollment":540,"conditions":541,"interventions":543},"NCT01018264","Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease",[89],"2014-08","2010-01",23,[542],"Overactive Bladder in Parkinson's Disease",[522],{"nctId":545,"briefTitle":546,"status":547,"phases":548,"primaryCompletion":549,"start":550,"enrollment":97,"conditions":551,"interventions":554},"NCT00584090","Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease","WITHDRAWN",[89],"2011-04","2007-11",[552,553],"Urinary Incontinence","Parkinson's Disease",[555],"Solifenacin Succinate",{"trials":557,"activeCount":97},[],{"intervention":559,"totalTrials":173,"cells":560},"Pregabalin",{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":567,"PHASE4":569,"NA":589},{"trials":562,"activeCount":97},[],{"trials":564,"activeCount":97},[],{"trials":566,"activeCount":97},[],{"trials":568,"activeCount":97},[],{"trials":570,"activeCount":97},[571,581],{"nctId":572,"briefTitle":573,"status":359,"phases":574,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":580},"NCT00584376","Pregabalin (Lyrica) for the Treatment of Essential Tremor",[89],"2010-11","2007-12",29,[579],"Essential Tremor",[559],{"nctId":582,"briefTitle":583,"status":547,"phases":584,"primaryCompletion":585,"completion":585,"start":550,"enrollment":97,"conditions":586,"interventions":588},"NCT00584246","Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome",[89],"2008-05",[587],"Restless Legs Syndrome",[559],{"trials":590,"activeCount":97},[],{"intervention":592,"totalTrials":93,"cells":593},"quetiapine SR",{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":602,"NA":616},{"trials":595,"activeCount":97},[],{"trials":597,"activeCount":97},[],{"trials":599,"activeCount":97},[],{"trials":601,"activeCount":97},[],{"trials":603,"activeCount":97},[604],{"nctId":605,"briefTitle":606,"status":359,"phases":607,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":611,"interventions":614},"NCT00579280","Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and\u002For GAD",[89],"2010-12","2007-07",224,[612,613,18],"Bipolar Disorder","Panic Disorder",[592,615],"divalproex sodium ER",{"trials":617,"activeCount":97},[],{"intervention":615,"totalTrials":93,"cells":619},{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":626,"PHASE4":628,"NA":634},{"trials":621,"activeCount":97},[],{"trials":623,"activeCount":97},[],{"trials":625,"activeCount":97},[],{"trials":627,"activeCount":97},[],{"trials":629,"activeCount":97},[630],{"nctId":605,"briefTitle":606,"status":359,"phases":631,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":632,"interventions":633},[89],[612,613,18],[592,615],{"trials":635,"activeCount":97},[],{"intervention":637,"totalTrials":93,"cells":638},"Acetaminophen",{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":647,"NA":661},{"trials":640,"activeCount":97},[],{"trials":642,"activeCount":97},[],{"trials":644,"activeCount":97},[],{"trials":646,"activeCount":97},[],{"trials":648,"activeCount":97},[649],{"nctId":650,"briefTitle":651,"status":198,"phases":652,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":659},"NCT03732469","Rectal Acetaminophen Use During Oocyte Retrievals to Reduce Post-Operative Opioid Utilization",[89],"2020-12-31","2021-03-01","2019-11-01",4,[658],"Opioid Use",[637,368,660],"Propofol",{"trials":662,"activeCount":97},[],{"intervention":660,"totalTrials":93,"cells":664},{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":671,"PHASE4":673,"NA":679},{"trials":666,"activeCount":97},[],{"trials":668,"activeCount":97},[],{"trials":670,"activeCount":97},[],{"trials":672,"activeCount":97},[],{"trials":674,"activeCount":97},[675],{"nctId":650,"briefTitle":651,"status":198,"phases":676,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":677,"interventions":678},[89],[658],[637,368,660],{"trials":680,"activeCount":97},[],{"intervention":682,"totalTrials":93,"cells":683},"2mg\u002Fkg\u002Fday Iron Sulfate",{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":690,"PHASE4":692,"NA":708},{"trials":685,"activeCount":97},[],{"trials":687,"activeCount":97},[],{"trials":689,"activeCount":97},[],{"trials":691,"activeCount":97},[],{"trials":693,"activeCount":97},[694],{"nctId":695,"briefTitle":696,"status":697,"phases":698,"primaryCompletion":699,"completion":700,"start":701,"enrollment":702,"conditions":703,"interventions":706},"NCT04497012","Iron Supplementation and Intestinal Health","UNKNOWN",[89],"2025-03-30","2025-07-31","2020-11-17",183,[704,705],"Anemia of Prematurity","Very Low Birth Weight Infant",[682,707],"6 mg\u002Fkg\u002Fday Iron Sulfate",{"trials":709,"activeCount":97},[],{"intervention":707,"totalTrials":93,"cells":711},{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":720,"NA":726},{"trials":713,"activeCount":97},[],{"trials":715,"activeCount":97},[],{"trials":717,"activeCount":97},[],{"trials":719,"activeCount":97},[],{"trials":721,"activeCount":97},[722],{"nctId":695,"briefTitle":696,"status":697,"phases":723,"primaryCompletion":699,"completion":700,"start":701,"enrollment":702,"conditions":724,"interventions":725},[89],[704,705],[682,707],{"trials":727,"activeCount":97},[],{"intervention":729,"totalTrials":93,"cells":730},"levetiracetam",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":739,"NA":748},{"trials":732,"activeCount":97},[],{"trials":734,"activeCount":97},[],{"trials":736,"activeCount":97},[],{"trials":738,"activeCount":97},[],{"trials":740,"activeCount":97},[741],{"nctId":742,"briefTitle":743,"status":547,"phases":744,"primaryCompletion":745,"completion":745,"start":576,"enrollment":97,"conditions":746,"interventions":747},"NCT00584025","Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease",[89],"2008-06",[553],[729],{"trials":749,"activeCount":97},[],{"intervention":751,"totalTrials":93,"cells":752},"Epoetin alfa",{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":757,"PHASE3":759,"PHASE4":761,"NA":773},{"trials":754,"activeCount":97},[],{"trials":756,"activeCount":97},[],{"trials":758,"activeCount":97},[],{"trials":760,"activeCount":97},[],{"trials":762,"activeCount":97},[763],{"nctId":764,"briefTitle":765,"status":198,"phases":766,"primaryCompletion":767,"completion":767,"start":609,"enrollment":768,"conditions":769,"interventions":771},"NCT00626574","Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa",[89],"2009-02",3,[770],"Subarachnoid Hemorrhage",[751,772],"Saline",{"trials":774,"activeCount":97},[],{"intervention":772,"totalTrials":93,"cells":776},{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":783,"PHASE4":785,"NA":791},{"trials":778,"activeCount":97},[],{"trials":780,"activeCount":97},[],{"trials":782,"activeCount":97},[],{"trials":784,"activeCount":97},[],{"trials":786,"activeCount":97},[787],{"nctId":764,"briefTitle":765,"status":198,"phases":788,"primaryCompletion":767,"completion":767,"start":609,"enrollment":768,"conditions":789,"interventions":790},[89],[770],[751,772],{"trials":792,"activeCount":97},[],{"intervention":794,"totalTrials":93,"cells":795},"sugammadex",{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":804,"NA":816},{"trials":797,"activeCount":97},[],{"trials":799,"activeCount":97},[],{"trials":801,"activeCount":97},[],{"trials":803,"activeCount":97},[],{"trials":805,"activeCount":97},[806],{"nctId":807,"briefTitle":808,"status":359,"phases":809,"primaryCompletion":810,"completion":810,"start":811,"enrollment":165,"conditions":812,"interventions":813},"NCT02860507","Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency",[89],"2018-02","2016-08",[244],[794,814,815],"Neostigmine","Glycopyrrolate",{"trials":817,"activeCount":97},[],{"intervention":814,"totalTrials":93,"cells":819},{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":828,"NA":834},{"trials":821,"activeCount":97},[],{"trials":823,"activeCount":97},[],{"trials":825,"activeCount":97},[],{"trials":827,"activeCount":97},[],{"trials":829,"activeCount":97},[830],{"nctId":807,"briefTitle":808,"status":359,"phases":831,"primaryCompletion":810,"completion":810,"start":811,"enrollment":165,"conditions":832,"interventions":833},[89],[244],[794,814,815],{"trials":835,"activeCount":97},[],{"intervention":815,"totalTrials":93,"cells":837},{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":844,"PHASE4":846,"NA":852},{"trials":839,"activeCount":97},[],{"trials":841,"activeCount":97},[],{"trials":843,"activeCount":97},[],{"trials":845,"activeCount":97},[],{"trials":847,"activeCount":97},[848],{"nctId":807,"briefTitle":808,"status":359,"phases":849,"primaryCompletion":810,"completion":810,"start":811,"enrollment":165,"conditions":850,"interventions":851},[89],[244],[794,814,815],{"trials":853,"activeCount":97},[],{"intervention":855,"totalTrials":93,"cells":856},"Cannabidiol",{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":865,"NA":877},{"trials":858,"activeCount":97},[],{"trials":860,"activeCount":97},[],{"trials":862,"activeCount":97},[],{"trials":864,"activeCount":97},[],{"trials":866,"activeCount":97},[867],{"nctId":868,"briefTitle":869,"status":359,"phases":870,"primaryCompletion":871,"completion":871,"start":872,"enrollment":873,"conditions":874,"interventions":876},"NCT04899050","Epidiolex in Typical Absence Seizures",[89],"2023-05-27","2021-07-30",14,[875],"Study the Efficacy of Epidiolex for Typical Absence Seizures",[855],{"trials":878,"activeCount":97},[],{"intervention":880,"totalTrials":93,"cells":881},"Oral Vancomycin",{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":886,"PHASE3":888,"PHASE4":890,"NA":903},{"trials":883,"activeCount":97},[],{"trials":885,"activeCount":97},[],{"trials":887,"activeCount":97},[],{"trials":889,"activeCount":97},[],{"trials":891,"activeCount":97},[892],{"nctId":893,"briefTitle":894,"status":198,"phases":895,"primaryCompletion":896,"completion":896,"start":897,"enrollment":898,"conditions":899,"interventions":902},"NCT04000555","Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)",[89],"2022-06-11","2019-09-01",26,[900,901],"Clostridium Difficile Infection","Clostridium Difficile Infection Recurrence",[880],{"trials":904,"activeCount":97},[],{"intervention":906,"totalTrials":93,"cells":907},"Febuxostat",{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":914,"PHASE4":916,"NA":929},{"trials":909,"activeCount":97},[],{"trials":911,"activeCount":97},[],{"trials":913,"activeCount":97},[],{"trials":915,"activeCount":97},[],{"trials":917,"activeCount":97},[918],{"nctId":919,"briefTitle":920,"status":359,"phases":921,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":927},"NCT01112982","An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.",[89],"2014-12","2010-05",74,[926],"Gout",[906,928],"Colchicine",{"trials":930,"activeCount":97},[],{"intervention":928,"totalTrials":93,"cells":932},{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":939,"PHASE4":941,"NA":947},{"trials":934,"activeCount":97},[],{"trials":936,"activeCount":97},[],{"trials":938,"activeCount":97},[],{"trials":940,"activeCount":97},[],{"trials":942,"activeCount":97},[943],{"nctId":919,"briefTitle":920,"status":359,"phases":944,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":945,"interventions":946},[89],[926],[906,928],{"trials":948,"activeCount":97},[],{"intervention":950,"totalTrials":93,"cells":951},"risperidone",{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":958,"PHASE4":960,"NA":970},{"trials":953,"activeCount":97},[],{"trials":955,"activeCount":97},[],{"trials":957,"activeCount":97},[],{"trials":959,"activeCount":97},[],{"trials":961,"activeCount":97},[962],{"nctId":963,"briefTitle":964,"status":359,"phases":965,"completion":966,"start":967,"enrollment":111,"conditions":968,"interventions":969},"NCT00167479","A Study of Risperidone Monotherapy in Bipolar Anxiety",[89],"2006-09","2003-09",[612,613,18],[950],{"trials":971,"activeCount":97},[],{"intervention":973,"totalTrials":93,"cells":974},"Selegiline",{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":981,"PHASE4":983,"NA":996},{"trials":976,"activeCount":97},[],{"trials":978,"activeCount":97},[],{"trials":980,"activeCount":97},[],{"trials":982,"activeCount":97},[],{"trials":984,"activeCount":97},[985],{"nctId":986,"briefTitle":987,"status":697,"phases":988,"primaryCompletion":989,"completion":990,"start":991,"enrollment":16,"conditions":992,"interventions":994},"NCT02225548","Sagene 2014 - Parkinson's Disease and Erectile Dysfunction",[89],"2018-12","2019-01","2014-09",[553,993],"Erectile Dysfunction",[973,995],"Tadalafil",{"trials":997,"activeCount":97},[],{"intervention":995,"totalTrials":93,"cells":999},{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1006,"PHASE4":1008,"NA":1014},{"trials":1001,"activeCount":97},[],{"trials":1003,"activeCount":97},[],{"trials":1005,"activeCount":97},[],{"trials":1007,"activeCount":97},[],{"trials":1009,"activeCount":97},[1010],{"nctId":986,"briefTitle":987,"status":697,"phases":1011,"primaryCompletion":989,"completion":990,"start":991,"enrollment":16,"conditions":1012,"interventions":1013},[89],[553,993],[973,995],{"trials":1015,"activeCount":97},[],{"intervention":1017,"totalTrials":93,"cells":1018},"Misoprostol 50 mcg pesssary",{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1023,"PHASE3":1025,"PHASE4":1027,"NA":1040},{"trials":1020,"activeCount":97},[],{"trials":1022,"activeCount":97},[],{"trials":1024,"activeCount":97},[],{"trials":1026,"activeCount":97},[],{"trials":1028,"activeCount":97},[1029],{"nctId":1030,"briefTitle":1031,"status":547,"phases":1032,"primaryCompletion":1033,"completion":1034,"start":1035,"enrollment":97,"conditions":1036,"interventions":1038},"NCT03547778","Misoprostol in Office Hysteroscopy and Endometrial Biopsy",[89],"2019-12-31","2020-03-25","2018-09-01",[1037],"Office Hysteroscopy and Endometrial Biopsy",[1017,1039],"Placebos",{"trials":1041,"activeCount":97},[],{"intervention":1039,"totalTrials":93,"cells":1043},{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1048,"PHASE3":1050,"PHASE4":1052,"NA":1058},{"trials":1045,"activeCount":97},[],{"trials":1047,"activeCount":97},[],{"trials":1049,"activeCount":97},[],{"trials":1051,"activeCount":97},[],{"trials":1053,"activeCount":97},[1054],{"nctId":1030,"briefTitle":1031,"status":547,"phases":1055,"primaryCompletion":1033,"completion":1034,"start":1035,"enrollment":97,"conditions":1056,"interventions":1057},[89],[1037],[1017,1039],{"trials":1059,"activeCount":97},[],{"intervention":1061,"totalTrials":93,"cells":1062},"furosemide",{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1067,"PHASE3":1069,"PHASE4":1071,"NA":1085},{"trials":1064,"activeCount":97},[],{"trials":1066,"activeCount":97},[],{"trials":1068,"activeCount":97},[],{"trials":1070,"activeCount":97},[],{"trials":1072,"activeCount":97},[1073],{"nctId":1074,"briefTitle":1075,"status":359,"phases":1076,"primaryCompletion":1077,"completion":1078,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1083},"NCT02960412","Effect of Furosemide on Confirmation of Ureteral Patency During Routine Cystoscopy",[89],"2018-03-31","2018-06-30","2017-05-01",150,[1082],"Cystoscopy",[1061,1084],"Normal Saline",{"trials":1086,"activeCount":97},[],{"intervention":1084,"totalTrials":93,"cells":1088},{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1093,"PHASE3":1095,"PHASE4":1097,"NA":1103},{"trials":1090,"activeCount":97},[],{"trials":1092,"activeCount":97},[],{"trials":1094,"activeCount":97},[],{"trials":1096,"activeCount":97},[],{"trials":1098,"activeCount":97},[1099],{"nctId":1074,"briefTitle":1075,"status":359,"phases":1100,"primaryCompletion":1077,"completion":1078,"start":1079,"enrollment":1080,"conditions":1101,"interventions":1102},[89],[1082],[1061,1084],{"trials":1104,"activeCount":97},[],{"intervention":1106,"totalTrials":93,"cells":1107},"Treatment with Apremilast",{"EARLY_PHASE1":1108,"PHASE1":1110,"PHASE2":1112,"PHASE3":1114,"PHASE4":1116,"NA":1127},{"trials":1109,"activeCount":97},[],{"trials":1111,"activeCount":97},[],{"trials":1113,"activeCount":97},[],{"trials":1115,"activeCount":97},[],{"trials":1117,"activeCount":97},[1118],{"nctId":1119,"briefTitle":1120,"status":547,"phases":1121,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":97,"conditions":1124,"interventions":1126},"NCT02558361","Treatment With Apremilast in Patients With Psoriatic Arthritis",[89],"2016-10","2016-04",[1125],"Psoriatic Arthritis",[1106],{"trials":1128,"activeCount":97},[],{"intervention":1130,"totalTrials":768,"cells":1131},"cyproheptadine hydrochloride",{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1166,"PHASE4":1178,"NA":1180},{"trials":1133,"activeCount":97},[],{"trials":1135,"activeCount":97},[],{"trials":1137,"activeCount":97},[1138,1156],{"nctId":1139,"briefTitle":1140,"status":359,"phases":1141,"primaryCompletion":1142,"completion":1142,"start":1143,"enrollment":1144,"conditions":1145,"interventions":1154},"NCT00066248","Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment",[87],"2007-08","2003-06",70,[1146,1147,1148,1149,1150,1151,1152,1153],"Brain Tumor","Central Nervous System Tumors","Cachexia","Leukemia","Lymphoma","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Diseases","Unspecified Childhood Solid Tumor, Protocol Specific",[1130,1155],"megestrol acetate",{"nctId":1157,"briefTitle":1158,"status":198,"phases":1159,"primaryCompletion":1160,"completion":1160,"start":1161,"enrollment":19,"conditions":1162,"interventions":1165},"NCT00949117","Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer",[87],"2011-11","2009-09",[1149,1150,1163,1151,1153,1164],"Malnutrition","Weight Changes",[1130],{"trials":1167,"activeCount":97},[1168],{"nctId":1169,"briefTitle":1170,"status":198,"phases":1171,"primaryCompletion":1172,"completion":1172,"start":1173,"enrollment":1174,"conditions":1175,"interventions":1177},"NCT01132547","Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer",[88],"2014-01","2010-06",22,[1176],"Cancer",[1130],{"trials":1179,"activeCount":97},[],{"trials":1181,"activeCount":97},[],{"intervention":1183,"totalTrials":173,"cells":1184},"varenicline",{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1200,"PHASE4":1210,"NA":1212},{"trials":1186,"activeCount":97},[],{"trials":1188,"activeCount":97},[],{"trials":1190,"activeCount":97},[1191],{"nctId":1192,"briefTitle":1193,"status":359,"phases":1194,"primaryCompletion":549,"completion":549,"start":1195,"enrollment":1196,"conditions":1197,"interventions":1199},"NCT00992771","Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3",[87],"2009-10",20,[1198],"Spinocerebellar Ataxia Type 3",[1183],{"trials":1201,"activeCount":97},[1202],{"nctId":1203,"briefTitle":1204,"status":198,"phases":1205,"primaryCompletion":923,"completion":923,"start":1206,"enrollment":9,"conditions":1207,"interventions":1209},"NCT00803868","Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia",[87,88],"2009-05",[1208],"Friedreich's Ataxia",[1183],{"trials":1211,"activeCount":97},[],{"trials":1213,"activeCount":97},[],{"intervention":1215,"totalTrials":173,"cells":1216},"D-cycloserine",{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1221,"PHASE3":1231,"PHASE4":1245,"NA":1247},{"trials":1218,"activeCount":97},[],{"trials":1220,"activeCount":97},[],{"trials":1222,"activeCount":97},[1223],{"nctId":1224,"briefTitle":1225,"status":359,"phases":1226,"primaryCompletion":1227,"completion":1227,"start":1228,"enrollment":405,"conditions":1229,"interventions":1230},"NCT00864123","D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder",[87],"2009-11","2008-01",[21],[1215],{"trials":1232,"activeCount":97},[1233],{"nctId":1234,"briefTitle":1235,"status":359,"phases":1236,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":1240,"conditions":1241,"interventions":1242},"NCT01411774","D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)",[88],"2016-06","2017-06","2011-06",142,[21],[1243,1244],"d-cycloserine","Pill placebo",{"trials":1246,"activeCount":97},[],{"trials":1248,"activeCount":97},[],{"intervention":1250,"totalTrials":93,"cells":1251},"Lidocaine Hcl 2% Jelly",{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1256,"PHASE3":1258,"PHASE4":1271,"NA":1273},{"trials":1253,"activeCount":97},[],{"trials":1255,"activeCount":97},[],{"trials":1257,"activeCount":97},[],{"trials":1259,"activeCount":97},[1260],{"nctId":1261,"briefTitle":1262,"status":359,"phases":1263,"primaryCompletion":1264,"completion":1265,"start":1266,"enrollment":139,"conditions":1267,"interventions":1270},"NCT05493735","Lidocaine for Pessary Check Pain Reduction",[88],"2023-06-23","2023-06-30","2022-09-08",[1268,1269],"Pelvic Organ Prolapse","Stress Urinary Incontinence",[1250],{"trials":1272,"activeCount":97},[],{"trials":1274,"activeCount":97},[],{"intervention":1276,"totalTrials":93,"cells":1277},"Lidocaine",{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1284,"PHASE4":1295,"NA":1297},{"trials":1279,"activeCount":97},[],{"trials":1281,"activeCount":97},[],{"trials":1283,"activeCount":97},[],{"trials":1285,"activeCount":97},[1286],{"nctId":1287,"briefTitle":1288,"status":359,"phases":1289,"primaryCompletion":1290,"completion":991,"start":1291,"enrollment":1196,"conditions":1292,"interventions":1294},"NCT01944098","Intraoperative Lidocaine Infusion for Postoperative Pain Management in Obese Patients",[88],"2014-07","2013-08",[1293],"Bariatric Surgical Pain",[1276],{"trials":1296,"activeCount":97},[],{"trials":1298,"activeCount":97},[],{"intervention":1300,"totalTrials":93,"cells":1301},"Apixaban",{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1306,"PHASE3":1308,"PHASE4":1322,"NA":1324},{"trials":1303,"activeCount":97},[],{"trials":1305,"activeCount":97},[],{"trials":1307,"activeCount":97},[],{"trials":1309,"activeCount":97},[1310],{"nctId":1311,"briefTitle":1312,"status":359,"phases":1313,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":1316,"conditions":1317,"interventions":1320},"NCT02283294","Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation",[88],"2019-06","2015-04",91,[1318,1319,429],"Transient Ischemic Attack","Stroke",[1300,1321],"Warfarin",{"trials":1323,"activeCount":97},[],{"trials":1325,"activeCount":97},[],{"intervention":1321,"totalTrials":93,"cells":1327},{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1332,"PHASE3":1334,"PHASE4":1340,"NA":1342},{"trials":1329,"activeCount":97},[],{"trials":1331,"activeCount":97},[],{"trials":1333,"activeCount":97},[],{"trials":1335,"activeCount":97},[1336],{"nctId":1311,"briefTitle":1312,"status":359,"phases":1337,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":1316,"conditions":1338,"interventions":1339},[88],[1318,1319,429],[1300,1321],{"trials":1341,"activeCount":97},[],{"trials":1343,"activeCount":97},[],{"intervention":1345,"totalTrials":93,"cells":1346},"Doxycycline and Rifampin",{"EARLY_PHASE1":1347,"PHASE1":1349,"PHASE2":1351,"PHASE3":1353,"PHASE4":1366,"NA":1368},{"trials":1348,"activeCount":97},[],{"trials":1350,"activeCount":97},[],{"trials":1352,"activeCount":97},[],{"trials":1354,"activeCount":97},[1355],{"nctId":1356,"briefTitle":1357,"status":359,"phases":1358,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":202,"conditions":1361,"interventions":1364},"NCT00351273","Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria",[88],"2008-09","2006-05",[1362,1363],"Arthritis, Reactive","Reiter Disease",[1345,1365],"Azithromycin and Rifampin",{"trials":1367,"activeCount":97},[],{"trials":1369,"activeCount":97},[],{"intervention":1365,"totalTrials":93,"cells":1371},{"EARLY_PHASE1":1372,"PHASE1":1374,"PHASE2":1376,"PHASE3":1378,"PHASE4":1384,"NA":1386},{"trials":1373,"activeCount":97},[],{"trials":1375,"activeCount":97},[],{"trials":1377,"activeCount":97},[],{"trials":1379,"activeCount":97},[1380],{"nctId":1356,"briefTitle":1357,"status":359,"phases":1381,"primaryCompletion":1359,"completion":1359,"start":1360,"enrollment":202,"conditions":1382,"interventions":1383},[88],[1362,1363],[1345,1365],{"trials":1385,"activeCount":97},[],{"trials":1387,"activeCount":97},[],{"intervention":1389,"totalTrials":93,"cells":1390},".5% bupivacaine with epinephrine",{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1397,"PHASE4":1409,"NA":1411},{"trials":1392,"activeCount":97},[],{"trials":1394,"activeCount":97},[],{"trials":1396,"activeCount":97},[],{"trials":1398,"activeCount":97},[1399],{"nctId":1400,"briefTitle":1401,"status":359,"phases":1402,"completion":1403,"start":1404,"enrollment":1405,"conditions":1406,"interventions":1408},"NCT00298571","Cesarean Delivery and Post-operative Pain Management With Local Anesthesia",[87,88],"2007-10","2006-02",100,[1407],"Pain, Postoperative",[1389],{"trials":1410,"activeCount":97},[],{"trials":1412,"activeCount":97},[],{"intervention":1414,"totalTrials":93,"cells":1415},"glutamic acid",{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1422,"PHASE4":1436,"NA":1438},{"trials":1417,"activeCount":97},[],{"trials":1419,"activeCount":97},[],{"trials":1421,"activeCount":97},[],{"trials":1423,"activeCount":97},[1424],{"nctId":1425,"briefTitle":1426,"status":359,"phases":1427,"primaryCompletion":1428,"completion":1428,"start":1429,"enrollment":1430,"conditions":1431,"interventions":1435},"NCT00369564","Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer",[88],"2012-11","2007-05",250,[1432,1149,1150,1433,1434,447],"Kidney Cancer","Neurotoxicity","Peripheral Neuropathy",[1414],{"trials":1437,"activeCount":97},[],{"trials":1439,"activeCount":97},[],{"intervention":1244,"totalTrials":93,"cells":1441},{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1448,"PHASE4":1454,"NA":1456},{"trials":1443,"activeCount":97},[],{"trials":1445,"activeCount":97},[],{"trials":1447,"activeCount":97},[],{"trials":1449,"activeCount":97},[1450],{"nctId":1234,"briefTitle":1235,"status":359,"phases":1451,"primaryCompletion":1237,"completion":1238,"start":1239,"enrollment":1240,"conditions":1452,"interventions":1453},[88],[21],[1243,1244],{"trials":1455,"activeCount":97},[],{"trials":1457,"activeCount":97},[],{"intervention":1459,"totalTrials":93,"cells":1460},"Omegaven",{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1467,"PHASE4":1479,"NA":1481},{"trials":1462,"activeCount":97},[],{"trials":1464,"activeCount":97},[],{"trials":1466,"activeCount":97},[],{"trials":1468,"activeCount":97},[1469],{"nctId":1470,"briefTitle":1471,"status":359,"phases":1472,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":173,"conditions":1475,"interventions":1478},"NCT03662282","Omegaven as Alternative Parenteral Fat Nutrition",[88],"2019-01-07","2018-10-23",[1476,1477],"Cholestasis","Cholestasis of Parenteral Nutrition",[1459],{"trials":1480,"activeCount":97},[],{"trials":1482,"activeCount":97},[],{"intervention":1484,"totalTrials":93,"cells":1485},"17-Hydroxyprogesterone Capronate",{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1492,"PHASE4":1505,"NA":1507},{"trials":1487,"activeCount":97},[],{"trials":1489,"activeCount":97},[],{"trials":1491,"activeCount":97},[],{"trials":1493,"activeCount":97},[1494],{"nctId":1495,"briefTitle":1496,"status":359,"phases":1497,"primaryCompletion":109,"completion":1498,"start":1499,"enrollment":1500,"conditions":1501,"interventions":1504},"NCT03433040","17OHP-C Dosing Among Obese Pregnant Women",[88],"2021-07-14","2017-08-23",44,[1502,1503],"Premature Birth","Absorption; Chemicals",[1484],{"trials":1506,"activeCount":97},[],{"trials":1508,"activeCount":97},[],{"intervention":1510,"totalTrials":93,"cells":1511},"Mannitol",{"EARLY_PHASE1":1512,"PHASE1":1514,"PHASE2":1516,"PHASE3":1518,"PHASE4":1530,"NA":1532},{"trials":1513,"activeCount":97},[],{"trials":1515,"activeCount":97},[],{"trials":1517,"activeCount":97},[],{"trials":1519,"activeCount":97},[1520],{"nctId":1521,"briefTitle":1522,"status":697,"phases":1523,"primaryCompletion":1524,"start":1525,"enrollment":1526,"conditions":1527,"interventions":1529},"NCT02570971","Mannitol Versus Supportive Care in Ciguatera Fish Poisoning",[88],"2018-06","2015-10",200,[1528],"Ciguatoxin",[1510],{"trials":1531,"activeCount":97},[],{"trials":1533,"activeCount":97},[],{"intervention":1535,"totalTrials":93,"cells":1536},"Ketamine",{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1543,"PHASE4":1553,"NA":1555},{"trials":1538,"activeCount":97},[],{"trials":1540,"activeCount":97},[],{"trials":1542,"activeCount":97},[],{"trials":1544,"activeCount":97},[1545],{"nctId":1546,"briefTitle":1547,"status":547,"phases":1548,"primaryCompletion":897,"completion":655,"start":1035,"enrollment":97,"conditions":1549,"interventions":1552},"NCT03502421","Ketamine Sickle Cell Disease",[88],[1550,1551],"SC Disease","Pain, Chronic",[1535],{"trials":1554,"activeCount":97},[],{"trials":1556,"activeCount":97},[],{"intervention":1558,"totalTrials":93,"cells":1559},"Superior laryngeal nerve block - Intervention",{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1566,"PHASE4":1580,"NA":1582},{"trials":1561,"activeCount":97},[],{"trials":1563,"activeCount":97},[],{"trials":1565,"activeCount":97},[],{"trials":1567,"activeCount":97},[1568],{"nctId":1569,"briefTitle":1570,"status":697,"phases":1571,"primaryCompletion":1572,"completion":1572,"start":1573,"enrollment":1574,"conditions":1575,"interventions":1578},"NCT04468542","Randomized Placebo-controlled Analysis of Superior Laryngeal Nerve Block for Neurogenic Cough",[88],"2022-12","2021-01-12",65,[1576,1577],"Cough","Nerve Block",[1558,1579],"Superior laryngeal nerve block - Placebo",{"trials":1581,"activeCount":97},[],{"trials":1583,"activeCount":97},[],{"intervention":1579,"totalTrials":93,"cells":1585},{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1592,"PHASE4":1598,"NA":1600},{"trials":1587,"activeCount":97},[],{"trials":1589,"activeCount":97},[],{"trials":1591,"activeCount":97},[],{"trials":1593,"activeCount":97},[1594],{"nctId":1569,"briefTitle":1570,"status":697,"phases":1595,"primaryCompletion":1572,"completion":1572,"start":1573,"enrollment":1574,"conditions":1596,"interventions":1597},[88],[1576,1577],[1558,1579],{"trials":1599,"activeCount":97},[],{"trials":1601,"activeCount":97},[],{"intervention":1603,"totalTrials":93,"cells":1604},"Opioid Anesthesia",{"EARLY_PHASE1":1605,"PHASE1":1607,"PHASE2":1609,"PHASE3":1611,"PHASE4":1625,"NA":1627},{"trials":1606,"activeCount":97},[],{"trials":1608,"activeCount":97},[],{"trials":1610,"activeCount":97},[],{"trials":1612,"activeCount":97},[1613],{"nctId":1614,"briefTitle":1615,"status":697,"phases":1616,"primaryCompletion":1617,"completion":1618,"start":1619,"enrollment":1405,"conditions":1620,"interventions":1623},"NCT03367988","Opioid Free Anesthesia vs. Opioid Anesthesia Techniques.",[87,88],"2023-01","2023-08","2018-12-01",[1621,1622],"Analgesic Drug Dependence","Colectomy",[1603,1624],"Opioid-free Anesthesia",{"trials":1626,"activeCount":97},[],{"trials":1628,"activeCount":97},[],{"intervention":1624,"totalTrials":93,"cells":1630},{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1635,"PHASE3":1637,"PHASE4":1643,"NA":1645},{"trials":1632,"activeCount":97},[],{"trials":1634,"activeCount":97},[],{"trials":1636,"activeCount":97},[],{"trials":1638,"activeCount":97},[1639],{"nctId":1614,"briefTitle":1615,"status":697,"phases":1640,"primaryCompletion":1617,"completion":1618,"start":1619,"enrollment":1405,"conditions":1641,"interventions":1642},[87,88],[1621,1622],[1603,1624],{"trials":1644,"activeCount":97},[],{"trials":1646,"activeCount":97},[],{"intervention":1648,"totalTrials":93,"cells":1649},"prednisone",{"EARLY_PHASE1":1650,"PHASE1":1652,"PHASE2":1654,"PHASE3":1656,"PHASE4":1666,"NA":1668},{"trials":1651,"activeCount":97},[],{"trials":1653,"activeCount":97},[],{"trials":1655,"activeCount":97},[],{"trials":1657,"activeCount":97},[1658],{"nctId":1659,"briefTitle":1660,"status":359,"phases":1661,"primaryCompletion":608,"completion":1662,"start":576,"enrollment":165,"conditions":1663,"interventions":1665},"NCT00580229","A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.",[87,88],"2011-12",[1664],"Rheumatoid Arthritis",[1648],{"trials":1667,"activeCount":97},[],{"trials":1669,"activeCount":97},[],{"intervention":1671,"totalTrials":93,"cells":1672},"Abatacept",{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1693,"NA":1695},{"trials":1674,"activeCount":97},[],{"trials":1676,"activeCount":97},[],{"trials":1678,"activeCount":97},[],{"trials":1680,"activeCount":97},[1681],{"nctId":1682,"briefTitle":1683,"status":359,"phases":1684,"primaryCompletion":1685,"completion":1686,"start":1687,"enrollment":1574,"conditions":1688,"interventions":1692},"NCT02108860","Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)",[88],"2023-07-25","2023-12-20","2015-04-25",[1689,265,1690,1691],"Granulomatosis With Polyangiitis (Wegener's)","Wegener's Granulomatosis","ANCA-Associated Vasculitis",[1671],{"trials":1694,"activeCount":97},[],{"trials":1696,"activeCount":97},[],{"intervention":1698,"totalTrials":93,"cells":1699},"Coconut Oil Beverage",{"EARLY_PHASE1":1700,"PHASE1":1702,"PHASE2":1704,"PHASE3":1706,"PHASE4":1718,"NA":1720},{"trials":1701,"activeCount":97},[],{"trials":1703,"activeCount":97},[],{"trials":1705,"activeCount":97},[],{"trials":1707,"activeCount":97},[1708],{"nctId":1709,"briefTitle":1710,"status":198,"phases":1711,"primaryCompletion":1712,"completion":1712,"start":1713,"enrollment":1714,"conditions":1715,"interventions":1717},"NCT01883648","Study to Evaluate Coconut Oil for Alzheimer's Disease",[87,88],"2017-02-01","2013-06",21,[1716],"Alzheimer's Disease",[1698],{"trials":1719,"activeCount":97},[],{"trials":1721,"activeCount":97},[],{"intervention":1723,"totalTrials":173,"cells":1724},"modafinil",{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1754,"PHASE4":1756,"NA":1758},{"trials":1726,"activeCount":97},[],{"trials":1728,"activeCount":97},[],{"trials":1730,"activeCount":97},[1731,1743],{"nctId":1732,"briefTitle":1733,"status":198,"phases":1734,"primaryCompletion":1428,"completion":1735,"start":1736,"enrollment":93,"conditions":1737,"interventions":1741},"NCT01348607","Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy",[87],"2012-12","2010-07",[1738,1739,1740],"Central Nervous System Tumor, Pediatric","Fatigue","Specific Disorders of Sleep",[1742,1723],"methylphenidate hydrochloride",{"nctId":1744,"briefTitle":1745,"status":359,"phases":1746,"primaryCompletion":811,"completion":811,"start":1747,"enrollment":1748,"conditions":1749,"interventions":1753},"NCT01381718","Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor",[87],"2011-08",112,[1750,1751,1739,1433,1752],"Brain and Central Nervous System Tumors","Cognitive\u002FFunctional Effects","Psychosocial Effects of Cancer and Its Treatment",[1723],{"trials":1755,"activeCount":97},[],{"trials":1757,"activeCount":97},[],{"trials":1759,"activeCount":97},[],{"intervention":1761,"totalTrials":93,"cells":1762},"quetiapine",{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1767,"PHASE3":1780,"PHASE4":1782,"NA":1784},{"trials":1764,"activeCount":97},[],{"trials":1766,"activeCount":97},[],{"trials":1768,"activeCount":97},[1769],{"nctId":1770,"briefTitle":1771,"status":198,"phases":1772,"primaryCompletion":1773,"completion":1774,"start":1775,"enrollment":1776,"conditions":1777,"interventions":1779},"NCT00584688","A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study",[87],"2009-06","2009-08","2007-02",24,[1778],"Anorexia Nervosa",[1761],{"trials":1781,"activeCount":97},[],{"trials":1783,"activeCount":97},[],{"trials":1785,"activeCount":97},[],{"intervention":1787,"totalTrials":93,"cells":1788},"Coreg CR®",{"EARLY_PHASE1":1789,"PHASE1":1791,"PHASE2":1793,"PHASE3":1806,"PHASE4":1808,"NA":1810},{"trials":1790,"activeCount":97},[],{"trials":1792,"activeCount":97},[],{"trials":1794,"activeCount":97},[1795],{"nctId":1796,"briefTitle":1797,"status":359,"phases":1798,"primaryCompletion":1799,"completion":1800,"start":200,"enrollment":1801,"conditions":1802,"interventions":1804},"NCT01009918","Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab",[87],"2017-08","2018-11",468,[23,1803],"Cardiac Toxicity",[1787,1805],"lisinopril",{"trials":1807,"activeCount":97},[],{"trials":1809,"activeCount":97},[],{"trials":1811,"activeCount":97},[],{"intervention":1805,"totalTrials":93,"cells":1813},{"EARLY_PHASE1":1814,"PHASE1":1816,"PHASE2":1818,"PHASE3":1824,"PHASE4":1826,"NA":1828},{"trials":1815,"activeCount":97},[],{"trials":1817,"activeCount":97},[],{"trials":1819,"activeCount":97},[1820],{"nctId":1796,"briefTitle":1797,"status":359,"phases":1821,"primaryCompletion":1799,"completion":1800,"start":200,"enrollment":1801,"conditions":1822,"interventions":1823},[87],[23,1803],[1787,1805],{"trials":1825,"activeCount":97},[],{"trials":1827,"activeCount":97},[],{"trials":1829,"activeCount":97},[],{"intervention":1831,"totalTrials":93,"cells":1832},"Keppra",{"EARLY_PHASE1":1833,"PHASE1":1835,"PHASE2":1837,"PHASE3":1848,"PHASE4":1850,"NA":1852},{"trials":1834,"activeCount":97},[],{"trials":1836,"activeCount":97},[],{"trials":1838,"activeCount":97},[1839],{"nctId":1840,"briefTitle":1841,"status":198,"phases":1842,"primaryCompletion":1403,"completion":1403,"start":1843,"enrollment":1844,"conditions":1845,"interventions":1847},"NCT00760318","Keppra for Cervical Dystonia",[87],"2005-11",17,[1846],"Cervical Dystonia",[1831],{"trials":1849,"activeCount":97},[],{"trials":1851,"activeCount":97},[],{"trials":1853,"activeCount":97},[],{"intervention":1855,"totalTrials":93,"cells":1856},"Azithromycin",{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1874,"PHASE4":1876,"NA":1878},{"trials":1858,"activeCount":97},[],{"trials":1860,"activeCount":97},[],{"trials":1862,"activeCount":97},[1863],{"nctId":1864,"briefTitle":1865,"status":359,"phases":1866,"primaryCompletion":922,"completion":922,"start":1867,"enrollment":1868,"conditions":1869,"interventions":1873},"NCT01617083","Antibiotic Treatment Trial for the PANDAS\u002FPANS Phenotype",[87],"2012-05",47,[1870,1871,1872],"PANS","PANDAS","Obsessive Compulsive Disorder (OCD)",[1855],{"trials":1875,"activeCount":97},[],{"trials":1877,"activeCount":97},[],{"trials":1879,"activeCount":97},[],{"intervention":1742,"totalTrials":93,"cells":1881},{"EARLY_PHASE1":1882,"PHASE1":1884,"PHASE2":1886,"PHASE3":1892,"PHASE4":1894,"NA":1896},{"trials":1883,"activeCount":97},[],{"trials":1885,"activeCount":97},[],{"trials":1887,"activeCount":97},[1888],{"nctId":1732,"briefTitle":1733,"status":198,"phases":1889,"primaryCompletion":1428,"completion":1735,"start":1736,"enrollment":93,"conditions":1890,"interventions":1891},[87],[1738,1739,1740],[1742,1723],{"trials":1893,"activeCount":97},[],{"trials":1895,"activeCount":97},[],{"trials":1897,"activeCount":97},[],{"intervention":1899,"totalTrials":93,"cells":1900},"Clostridium Histolyticum Collagenase",{"EARLY_PHASE1":1901,"PHASE1":1903,"PHASE2":1905,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1902,"activeCount":97},[],{"trials":1904,"activeCount":97},[],{"trials":1906,"activeCount":97},[1907],{"nctId":1908,"briefTitle":1909,"status":359,"phases":1910,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":1915,"interventions":1917},"NCT02948842","Clostridium Histolyticum Collagenase Injection for Urethral Disease",[87],"2023-03-04","2023-04-12","2020-05-22",5,[1916],"Urethral Stricture",[1899],{"trials":1919,"activeCount":97},[],{"trials":1921,"activeCount":97},[],{"trials":1923,"activeCount":97},[],{"intervention":1925,"totalTrials":93,"cells":1926},"Paliperidone",{"EARLY_PHASE1":1927,"PHASE1":1929,"PHASE2":1931,"PHASE3":1942,"PHASE4":1944,"NA":1946},{"trials":1928,"activeCount":97},[],{"trials":1930,"activeCount":97},[],{"trials":1932,"activeCount":97},[1933],{"nctId":1934,"briefTitle":1935,"status":359,"phases":1936,"primaryCompletion":1937,"completion":1937,"start":1403,"enrollment":1938,"conditions":1939,"interventions":1941},"NCT00632229","Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder",[87],"2013-09",34,[1940],"Obsessive-Compulsive Disorder",[1925],{"trials":1943,"activeCount":97},[],{"trials":1945,"activeCount":97},[],{"trials":1947,"activeCount":97},[],{"intervention":1949,"totalTrials":93,"cells":1950},"EPI-743 400mg",{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1966,"PHASE4":1968,"NA":1970},{"trials":1952,"activeCount":97},[],{"trials":1954,"activeCount":97},[],{"trials":1956,"activeCount":97},[1957],{"nctId":1958,"briefTitle":1959,"status":359,"phases":1960,"primaryCompletion":1961,"completion":1237,"start":1937,"enrollment":1962,"conditions":1963,"interventions":1964},"NCT01923584","A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease",[87],"2015-12",15,[553],[1949,1965],"EPI-743 200mg",{"trials":1967,"activeCount":97},[],{"trials":1969,"activeCount":97},[],{"trials":1971,"activeCount":97},[],{"intervention":1965,"totalTrials":93,"cells":1973},{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1978,"PHASE3":1984,"PHASE4":1986,"NA":1988},{"trials":1975,"activeCount":97},[],{"trials":1977,"activeCount":97},[],{"trials":1979,"activeCount":97},[1980],{"nctId":1958,"briefTitle":1959,"status":359,"phases":1981,"primaryCompletion":1961,"completion":1237,"start":1937,"enrollment":1962,"conditions":1982,"interventions":1983},[87],[553],[1949,1965],{"trials":1985,"activeCount":97},[],{"trials":1987,"activeCount":97},[],{"trials":1989,"activeCount":97},[],{"intervention":1991,"totalTrials":93,"cells":1992},"NT-020",{"EARLY_PHASE1":1993,"PHASE1":1995,"PHASE2":1997,"PHASE3":2009,"PHASE4":2011,"NA":2013},{"trials":1994,"activeCount":97},[],{"trials":1996,"activeCount":97},[],{"trials":1998,"activeCount":97},[1999],{"nctId":2000,"briefTitle":2001,"status":359,"phases":2002,"primaryCompletion":2003,"completion":2003,"start":2004,"enrollment":2005,"conditions":2006,"interventions":2008},"NCT01963767","Nutraceutical Effects on Long-Term Memory",[87],"2013-02","2011-05",139,[2007],"Aging",[1991],{"trials":2010,"activeCount":97},[],{"trials":2012,"activeCount":97},[],{"trials":2014,"activeCount":97},[],{"intervention":2016,"totalTrials":93,"cells":2017},"G-CSF; filgrastim",{"EARLY_PHASE1":2018,"PHASE1":2020,"PHASE2":2022,"PHASE3":2032,"PHASE4":2034,"NA":2036},{"trials":2019,"activeCount":97},[],{"trials":2021,"activeCount":97},[],{"trials":2023,"activeCount":97},[2024],{"nctId":2025,"briefTitle":2026,"status":359,"phases":2027,"primaryCompletion":2028,"completion":2028,"start":1773,"enrollment":2029,"conditions":2030,"interventions":2031},"NCT01617577","Efficacy and Safety of Filgrastim in Alzheimer's Disease",[86,87],"2012-02",8,[1716],[2016],{"trials":2033,"activeCount":97},[],{"trials":2035,"activeCount":97},[],{"trials":2037,"activeCount":97},[],{"intervention":2039,"totalTrials":93,"cells":2040},"IVIG",{"EARLY_PHASE1":2041,"PHASE1":2043,"PHASE2":2045,"PHASE3":2055,"PHASE4":2057,"NA":2059},{"trials":2042,"activeCount":97},[],{"trials":2044,"activeCount":97},[],{"trials":2046,"activeCount":97},[2047],{"nctId":2048,"briefTitle":2049,"status":359,"phases":2050,"primaryCompletion":2051,"completion":2051,"start":1747,"enrollment":1914,"conditions":2052,"interventions":2054},"NCT01350440","Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia",[87],"2013-07",[2053],"Spinocerebellar Ataxia",[2039],{"trials":2056,"activeCount":97},[],{"trials":2058,"activeCount":97},[],{"trials":2060,"activeCount":97},[],{"intervention":2062,"totalTrials":93,"cells":2063},"Adderall-XR®",{"EARLY_PHASE1":2064,"PHASE1":2066,"PHASE2":2068,"PHASE3":2079,"PHASE4":2081,"NA":2083},{"trials":2065,"activeCount":97},[],{"trials":2067,"activeCount":97},[],{"trials":2069,"activeCount":97},[2070],{"nctId":2071,"briefTitle":2072,"status":198,"phases":2073,"primaryCompletion":2074,"completion":966,"start":2075,"enrollment":263,"conditions":2076,"interventions":2077},"NCT00069927","Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression",[87],"2006-06","2003-08",[15,1433,1153],[2062,2078],"Concerta®",{"trials":2080,"activeCount":97},[],{"trials":2082,"activeCount":97},[],{"trials":2084,"activeCount":97},[],{"intervention":2078,"totalTrials":93,"cells":2086},{"EARLY_PHASE1":2087,"PHASE1":2089,"PHASE2":2091,"PHASE3":2097,"PHASE4":2099,"NA":2101},{"trials":2088,"activeCount":97},[],{"trials":2090,"activeCount":97},[],{"trials":2092,"activeCount":97},[2093],{"nctId":2071,"briefTitle":2072,"status":198,"phases":2094,"primaryCompletion":2074,"completion":966,"start":2075,"enrollment":263,"conditions":2095,"interventions":2096},[87],[15,1433,1153],[2062,2078],{"trials":2098,"activeCount":97},[],{"trials":2100,"activeCount":97},[],{"trials":2102,"activeCount":97},[],{"intervention":2104,"totalTrials":93,"cells":2105},"Decadron®",{"EARLY_PHASE1":2106,"PHASE1":2108,"PHASE2":2110,"PHASE3":2123,"PHASE4":2125,"NA":2127},{"trials":2107,"activeCount":97},[],{"trials":2109,"activeCount":97},[],{"trials":2111,"activeCount":97},[2112],{"nctId":2113,"briefTitle":2114,"status":198,"phases":2115,"primaryCompletion":1774,"completion":1227,"start":1403,"enrollment":24,"conditions":2116,"interventions":2119},"NCT00429702","Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy",[87],[2117,2118,1153],"Nausea","Vomiting",[2104,2120,2121,2122],"Benadryl®","Ativan®","ondansetron hydrochloride",{"trials":2124,"activeCount":97},[],{"trials":2126,"activeCount":97},[],{"trials":2128,"activeCount":97},[],{"intervention":2120,"totalTrials":93,"cells":2130},{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2141,"PHASE4":2143,"NA":2145},{"trials":2132,"activeCount":97},[],{"trials":2134,"activeCount":97},[],{"trials":2136,"activeCount":97},[2137],{"nctId":2113,"briefTitle":2114,"status":198,"phases":2138,"primaryCompletion":1774,"completion":1227,"start":1403,"enrollment":24,"conditions":2139,"interventions":2140},[87],[2117,2118,1153],[2104,2120,2121,2122],{"trials":2142,"activeCount":97},[],{"trials":2144,"activeCount":97},[],{"trials":2146,"activeCount":97},[],{"intervention":2121,"totalTrials":93,"cells":2148},{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2159,"PHASE4":2161,"NA":2163},{"trials":2150,"activeCount":97},[],{"trials":2152,"activeCount":97},[],{"trials":2154,"activeCount":97},[2155],{"nctId":2113,"briefTitle":2114,"status":198,"phases":2156,"primaryCompletion":1774,"completion":1227,"start":1403,"enrollment":24,"conditions":2157,"interventions":2158},[87],[2117,2118,1153],[2104,2120,2121,2122],{"trials":2160,"activeCount":97},[],{"trials":2162,"activeCount":97},[],{"trials":2164,"activeCount":97},[],{"intervention":2122,"totalTrials":93,"cells":2166},{"EARLY_PHASE1":2167,"PHASE1":2169,"PHASE2":2171,"PHASE3":2177,"PHASE4":2179,"NA":2181},{"trials":2168,"activeCount":97},[],{"trials":2170,"activeCount":97},[],{"trials":2172,"activeCount":97},[2173],{"nctId":2113,"briefTitle":2114,"status":198,"phases":2174,"primaryCompletion":1774,"completion":1227,"start":1403,"enrollment":24,"conditions":2175,"interventions":2176},[87],[2117,2118,1153],[2104,2120,2121,2122],{"trials":2178,"activeCount":97},[],{"trials":2180,"activeCount":97},[],{"trials":2182,"activeCount":97},[],{"intervention":2184,"totalTrials":93,"cells":2185},"Glutathione",{"EARLY_PHASE1":2186,"PHASE1":2188,"PHASE2":2190,"PHASE3":2199,"PHASE4":2201,"NA":2203},{"trials":2187,"activeCount":97},[],{"trials":2189,"activeCount":97},[],{"trials":2191,"activeCount":97},[2192],{"nctId":2193,"briefTitle":2194,"status":359,"phases":2195,"primaryCompletion":2196,"completion":2196,"start":967,"enrollment":1196,"conditions":2197,"interventions":2198},"NCT01177319","Glutathione (GSH) In The Treatment of Parkinson's Disease",[87],"2007-03",[553],[2184],{"trials":2200,"activeCount":97},[],{"trials":2202,"activeCount":97},[],{"trials":2204,"activeCount":97},[],{"intervention":2206,"totalTrials":93,"cells":2207},"EPI-743",{"EARLY_PHASE1":2208,"PHASE1":2210,"PHASE2":2212,"PHASE3":2221,"PHASE4":2223,"NA":2225},{"trials":2209,"activeCount":97},[],{"trials":2211,"activeCount":97},[],{"trials":2213,"activeCount":97},[2214],{"nctId":2215,"briefTitle":2216,"status":359,"phases":2217,"primaryCompletion":1237,"completion":1237,"start":2218,"enrollment":656,"conditions":2219,"interventions":2220},"NCT01962363","EPI-743 in Friedreich's Ataxia Point Mutations",[87],"2013-10",[1208],[2206],{"trials":2222,"activeCount":97},[],{"trials":2224,"activeCount":97},[],{"trials":2226,"activeCount":97},[],{"intervention":2228,"totalTrials":93,"cells":2229},"triptorelin",{"EARLY_PHASE1":2230,"PHASE1":2232,"PHASE2":2234,"PHASE3":2246,"PHASE4":2248,"NA":2250},{"trials":2231,"activeCount":97},[],{"trials":2233,"activeCount":97},[],{"trials":2235,"activeCount":97},[2236],{"nctId":2237,"briefTitle":2238,"status":198,"phases":2239,"primaryCompletion":585,"completion":585,"start":2240,"enrollment":2241,"conditions":2242,"interventions":2245},"NCT00090844","Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer",[87],"2004-07",49,[23,2243,2244],"Hormone Changes","Drug Toxicity",[2228],{"trials":2247,"activeCount":97},[],{"trials":2249,"activeCount":97},[],{"trials":2251,"activeCount":97},[],{"intervention":1155,"totalTrials":93,"cells":2253},{"EARLY_PHASE1":2254,"PHASE1":2256,"PHASE2":2258,"PHASE3":2264,"PHASE4":2266,"NA":2268},{"trials":2255,"activeCount":97},[],{"trials":2257,"activeCount":97},[],{"trials":2259,"activeCount":97},[2260],{"nctId":1139,"briefTitle":1140,"status":359,"phases":2261,"primaryCompletion":1142,"completion":1142,"start":1143,"enrollment":1144,"conditions":2262,"interventions":2263},[87],[1146,1147,1148,1149,1150,1151,1152,1153],[1130,1155],{"trials":2265,"activeCount":97},[],{"trials":2267,"activeCount":97},[],{"trials":2269,"activeCount":97},[],{"intervention":2271,"totalTrials":93,"cells":2272},"10cc injection of bupivacaine",{"EARLY_PHASE1":2273,"PHASE1":2275,"PHASE2":2287,"PHASE3":2289,"PHASE4":2291,"NA":2293},{"trials":2274,"activeCount":97},[],{"trials":2276,"activeCount":97},[2277],{"nctId":2278,"briefTitle":2279,"status":359,"phases":2280,"primaryCompletion":2281,"completion":2281,"start":2282,"enrollment":188,"conditions":2283,"interventions":2285},"NCT03729375","The Effect Of An Anesthetic Procedure On Post Operative Pain Management In Carpal Tunnel Release",[86],"2020-10-04","2018-10-04",[1407,2284],"Carpal Tunnel Syndrome",[2271,2286],"20cc injection of bupivacaine",{"trials":2288,"activeCount":97},[],{"trials":2290,"activeCount":97},[],{"trials":2292,"activeCount":97},[],{"trials":2294,"activeCount":97},[],{"intervention":2286,"totalTrials":93,"cells":2296},{"EARLY_PHASE1":2297,"PHASE1":2299,"PHASE2":2305,"PHASE3":2307,"PHASE4":2309,"NA":2311},{"trials":2298,"activeCount":97},[],{"trials":2300,"activeCount":97},[2301],{"nctId":2278,"briefTitle":2279,"status":359,"phases":2302,"primaryCompletion":2281,"completion":2281,"start":2282,"enrollment":188,"conditions":2303,"interventions":2304},[86],[1407,2284],[2271,2286],{"trials":2306,"activeCount":97},[],{"trials":2308,"activeCount":97},[],{"trials":2310,"activeCount":97},[],{"trials":2312,"activeCount":97},[],{"intervention":2314,"totalTrials":93,"cells":2315},"Intravenous Immune Globulin",{"EARLY_PHASE1":2316,"PHASE1":2318,"PHASE2":2328,"PHASE3":2330,"PHASE4":2332,"NA":2334},{"trials":2317,"activeCount":97},[],{"trials":2319,"activeCount":97},[2320],{"nctId":2321,"briefTitle":2322,"status":697,"phases":2323,"primaryCompletion":2324,"start":1315,"enrollment":16,"conditions":2325,"interventions":2327},"NCT02287064","An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias",[86],"2016-12",[2326],"Spinocerebellar Ataxias",[2314],{"trials":2329,"activeCount":97},[],{"trials":2331,"activeCount":97},[],{"trials":2333,"activeCount":97},[],{"trials":2335,"activeCount":97},[],{"intervention":2337,"totalTrials":93,"cells":2338},"biological\u002Fvaccine",{"EARLY_PHASE1":2339,"PHASE1":2341,"PHASE2":2352,"PHASE3":2354,"PHASE4":2356,"NA":2358},{"trials":2340,"activeCount":97},[],{"trials":2342,"activeCount":97},[2343],{"nctId":2344,"briefTitle":2345,"status":359,"phases":2346,"primaryCompletion":2347,"completion":2347,"start":2348,"enrollment":427,"conditions":2349,"interventions":2351},"NCT01621685","Human Safety of Capsaicin Inhalation Challenge Testing for Young and Older Men",[86],"2007-09","2004-09",[2350],"COPD",[2337],{"trials":2353,"activeCount":97},[],{"trials":2355,"activeCount":97},[],{"trials":2357,"activeCount":97},[],{"trials":2359,"activeCount":97},[],{"intervention":2361,"totalTrials":93,"cells":2362},"Estradiol vaginal cream",{"EARLY_PHASE1":2363,"PHASE1":2376,"PHASE2":2378,"PHASE3":2380,"PHASE4":2382,"NA":2384},{"trials":2364,"activeCount":97},[2365],{"nctId":2366,"briefTitle":2367,"status":198,"phases":2368,"primaryCompletion":2369,"completion":2369,"start":2370,"enrollment":2371,"conditions":2372,"interventions":2375},"NCT05458375","Vaginal Estradiol Use in Pessary Care",[85],"2023-04-26","2022-12-29",11,[1268,552,2373,2374],"Pessary Ulcer of Vagina","Vaginal Atrophy",[2361],{"trials":2377,"activeCount":97},[],{"trials":2379,"activeCount":97},[],{"trials":2381,"activeCount":97},[],{"trials":2383,"activeCount":97},[],{"trials":2385,"activeCount":97},[],{"intervention":368,"totalTrials":173,"cells":2387},{"EARLY_PHASE1":2388,"PHASE1":2390,"PHASE2":2392,"PHASE3":2394,"PHASE4":2396,"NA":2402},{"trials":2389,"activeCount":97},[],{"trials":2391,"activeCount":97},[],{"trials":2393,"activeCount":97},[],{"trials":2395,"activeCount":97},[],{"trials":2397,"activeCount":97},[2398],{"nctId":650,"briefTitle":651,"status":198,"phases":2399,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":2400,"interventions":2401},[89],[658],[637,368,660],{"trials":2403,"activeCount":97},[2404],{"nctId":357,"briefTitle":358,"status":359,"phases":2405,"primaryCompletion":361,"completion":362,"start":363,"enrollment":111,"conditions":2406,"interventions":2407},[90],[365,366],[368,224,368],{"intervention":2409,"totalTrials":173,"cells":2410},"losartan",{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2415,"PHASE3":2417,"PHASE4":2419,"NA":2421},{"trials":2412,"activeCount":97},[],{"trials":2414,"activeCount":97},[],{"trials":2416,"activeCount":97},[],{"trials":2418,"activeCount":97},[],{"trials":2420,"activeCount":97},[],{"trials":2422,"activeCount":97},[2423,2431],{"nctId":2424,"briefTitle":2425,"status":359,"phases":2426,"primaryCompletion":362,"completion":362,"start":2427,"enrollment":1196,"conditions":2428,"interventions":2430},"NCT00879879","Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis",[90],"2009-03",[2429],"Precancerous Condition",[2409],{"nctId":2432,"briefTitle":2433,"status":547,"phases":2434,"primaryCompletion":2435,"completion":2435,"start":2427,"enrollment":97,"conditions":2436,"interventions":2441},"NCT00880386","Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer",[90],"2010-04",[2437,2438,2439,2440],"Dyspnea","Lung Cancer","Pulmonary Complications","Radiation Fibrosis",[2442],"Losartan",{"intervention":2444,"totalTrials":93,"cells":2445},"Tysabri ®",{"EARLY_PHASE1":2446,"PHASE1":2448,"PHASE2":2450,"PHASE3":2452,"PHASE4":2454,"NA":2456},{"trials":2447,"activeCount":97},[],{"trials":2449,"activeCount":97},[],{"trials":2451,"activeCount":97},[],{"trials":2453,"activeCount":97},[],{"trials":2455,"activeCount":97},[],{"trials":2457,"activeCount":97},[2458],{"nctId":2459,"briefTitle":2460,"status":359,"phases":2461,"primaryCompletion":2462,"completion":2462,"start":2463,"enrollment":2464,"conditions":2465,"interventions":2466},"NCT01455220","The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis",[90],"2014-10","2011-01",45,[30],[2444],{"intervention":2468,"totalTrials":93,"cells":2469},"Methergine",{"EARLY_PHASE1":2470,"PHASE1":2472,"PHASE2":2474,"PHASE3":2476,"PHASE4":2478,"NA":2480},{"trials":2471,"activeCount":97},[],{"trials":2473,"activeCount":97},[],{"trials":2475,"activeCount":97},[],{"trials":2477,"activeCount":97},[],{"trials":2479,"activeCount":97},[],{"trials":2481,"activeCount":97},[2482],{"nctId":2483,"briefTitle":2484,"status":359,"phases":2485,"primaryCompletion":2463,"completion":2463,"start":2486,"enrollment":1500,"conditions":2487,"interventions":2489},"NCT00858832","Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine",[90],"2008-12",[2488],"Endometritis",[2468],{"intervention":2491,"totalTrials":93,"cells":2492},"microRNA",{"EARLY_PHASE1":2493,"PHASE1":2495,"PHASE2":2497,"PHASE3":2499,"PHASE4":2501,"NA":2503},{"trials":2494,"activeCount":97},[],{"trials":2496,"activeCount":97},[],{"trials":2498,"activeCount":97},[],{"trials":2500,"activeCount":97},[],{"trials":2502,"activeCount":97},[],{"trials":2504,"activeCount":97},[2505],{"nctId":2506,"briefTitle":2507,"status":359,"phases":2508,"primaryCompletion":2509,"completion":2509,"start":1747,"enrollment":898,"conditions":2510,"interventions":2513},"NCT01631773","A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only",[],"2012-06",[2511,2512],"Aspirin-exacerbated Respiratory Disease","Nasal Polyp",[2491],{"intervention":2515,"totalTrials":93,"cells":2516},"Hizentra",{"EARLY_PHASE1":2517,"PHASE1":2519,"PHASE2":2521,"PHASE3":2523,"PHASE4":2525,"NA":2527},{"trials":2518,"activeCount":97},[],{"trials":2520,"activeCount":97},[],{"trials":2522,"activeCount":97},[],{"trials":2524,"activeCount":97},[],{"trials":2526,"activeCount":97},[],{"trials":2528,"activeCount":97},[2529],{"nctId":2530,"briefTitle":2531,"status":697,"phases":2532,"primaryCompletion":2533,"completion":2533,"start":2534,"enrollment":165,"conditions":2535,"interventions":2537},"NCT01354587","Evaluation of Efficacy and Tolerability of Hizentra®",[90],"2012-08","2010-10",[2536],"Primary Immunodeficiency Disorders",[2515],{"intervention":2539,"totalTrials":93,"cells":2540},"Bacteriophage OX174",{"EARLY_PHASE1":2541,"PHASE1":2543,"PHASE2":2545,"PHASE3":2547,"PHASE4":2549,"NA":2551},{"trials":2542,"activeCount":97},[],{"trials":2544,"activeCount":97},[],{"trials":2546,"activeCount":97},[],{"trials":2548,"activeCount":97},[],{"trials":2550,"activeCount":97},[],{"trials":2552,"activeCount":97},[2553],{"nctId":2554,"briefTitle":2555,"status":697,"phases":2556,"primaryCompletion":1961,"completion":1961,"start":2557,"enrollment":1526,"conditions":2558,"interventions":2560},"NCT01617122","Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)",[90],"1995-10",[2559],"Primary Immune Deficiency Diseases",[2539],{"intervention":2562,"totalTrials":93,"cells":2563},"Diltiazem Hydrochloride",{"EARLY_PHASE1":2564,"PHASE1":2566,"PHASE2":2568,"PHASE3":2570,"PHASE4":2572,"NA":2574},{"trials":2565,"activeCount":97},[],{"trials":2567,"activeCount":97},[],{"trials":2569,"activeCount":97},[],{"trials":2571,"activeCount":97},[],{"trials":2573,"activeCount":97},[],{"trials":2575,"activeCount":97},[2576],{"nctId":2577,"briefTitle":2578,"status":547,"phases":2579,"primaryCompletion":991,"completion":991,"start":2580,"enrollment":97,"conditions":2581,"interventions":2586},"NCT01645826","Efficacy Study of Cardizem in Pulmonary Arterial Hypertension",[90],"2012-07",[2582,2583,2584,2585],"Idiopathic Pulmonary Arterial Hypertension","Primary Pulmonary Hypertension","Pulmonary Arterial Hypertension","Familial Primary Pulmonary Hypertension",[2562,2587],"Sugar Pill",{"intervention":2587,"totalTrials":93,"cells":2589},{"EARLY_PHASE1":2590,"PHASE1":2592,"PHASE2":2594,"PHASE3":2596,"PHASE4":2598,"NA":2600},{"trials":2591,"activeCount":97},[],{"trials":2593,"activeCount":97},[],{"trials":2595,"activeCount":97},[],{"trials":2597,"activeCount":97},[],{"trials":2599,"activeCount":97},[],{"trials":2601,"activeCount":97},[2602],{"nctId":2577,"briefTitle":2578,"status":547,"phases":2603,"primaryCompletion":991,"completion":991,"start":2580,"enrollment":97,"conditions":2604,"interventions":2605},[90],[2582,2583,2584,2585],[2562,2587],{"intervention":2607,"totalTrials":93,"cells":2608},"no intervention",{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2613,"PHASE3":2615,"PHASE4":2617,"NA":2619},{"trials":2610,"activeCount":97},[],{"trials":2612,"activeCount":97},[],{"trials":2614,"activeCount":97},[],{"trials":2616,"activeCount":97},[],{"trials":2618,"activeCount":97},[],{"trials":2620,"activeCount":97},[2621],{"nctId":2622,"briefTitle":2623,"status":547,"phases":2624,"primaryCompletion":2625,"start":2626,"enrollment":97,"conditions":2627,"interventions":2629},"NCT01631760","Identification of Plasma miRNAs as Potential Biomarkers in Asthma Exacerbation",[],"2014-02","2011-10",[2628],"Asthma",[2607],{"intervention":2631,"totalTrials":93,"cells":2632},"Tylenol",{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2639,"PHASE4":2641,"NA":2643},{"trials":2634,"activeCount":97},[],{"trials":2636,"activeCount":97},[],{"trials":2638,"activeCount":97},[],{"trials":2640,"activeCount":97},[],{"trials":2642,"activeCount":97},[],{"trials":2644,"activeCount":97},[2645],{"nctId":2646,"briefTitle":2647,"status":697,"phases":2648,"primaryCompletion":2649,"completion":2650,"start":1618,"enrollment":2651,"conditions":2652,"interventions":2654},"NCT05990868","Rectal Acetaminophen During Oocyte Retrievals",[90],"2024-08","2025-08",78,[2653],"Oocyte Retrieival and Post Operative Pain Control",[2631],{"intervention":2656,"totalTrials":93,"cells":2657},"Immune Globulin Subcutaneous",{"EARLY_PHASE1":2658,"PHASE1":2660,"PHASE2":2662,"PHASE3":2664,"PHASE4":2666,"NA":2668},{"trials":2659,"activeCount":97},[],{"trials":2661,"activeCount":97},[],{"trials":2663,"activeCount":97},[],{"trials":2665,"activeCount":97},[],{"trials":2667,"activeCount":97},[],{"trials":2669,"activeCount":97},[2670],{"nctId":2671,"briefTitle":2672,"status":359,"phases":2673,"primaryCompletion":2674,"completion":2675,"start":991,"enrollment":1962,"conditions":2676,"interventions":2678},"NCT02465359","Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",[90],"2018-03","2021-05",[2677],"Chronic Inflammatory Demyelinating Polyneuropathy",[2656],{"intervention":2680,"totalTrials":93,"cells":2681},"fluorouracil",{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2686,"PHASE3":2688,"PHASE4":2690,"NA":2692},{"trials":2683,"activeCount":97},[],{"trials":2685,"activeCount":97},[],{"trials":2687,"activeCount":97},[],{"trials":2689,"activeCount":97},[],{"trials":2691,"activeCount":97},[],{"trials":2693,"activeCount":97},[2694],{"nctId":2695,"briefTitle":2696,"status":697,"phases":2697,"start":2698,"conditions":2699,"interventions":2701},"NCT00079365","Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas",[90],"2001-05",[2700],"Pancreatic Cancer",[2680,2702],"gemcitabine hydrochloride",{"intervention":2702,"totalTrials":93,"cells":2704},{"EARLY_PHASE1":2705,"PHASE1":2707,"PHASE2":2709,"PHASE3":2711,"PHASE4":2713,"NA":2715},{"trials":2706,"activeCount":97},[],{"trials":2708,"activeCount":97},[],{"trials":2710,"activeCount":97},[],{"trials":2712,"activeCount":97},[],{"trials":2714,"activeCount":97},[],{"trials":2716,"activeCount":97},[2717],{"nctId":2695,"briefTitle":2696,"status":697,"phases":2718,"start":2698,"conditions":2719,"interventions":2720},[90],[2700],[2680,2702],{"intervention":2722,"totalTrials":93,"cells":2723},"Acetyl-L-Carnitine",{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2728,"PHASE3":2730,"PHASE4":2732,"NA":2734},{"trials":2725,"activeCount":97},[],{"trials":2727,"activeCount":97},[],{"trials":2729,"activeCount":97},[],{"trials":2731,"activeCount":97},[],{"trials":2733,"activeCount":97},[],{"trials":2735,"activeCount":97},[2736],{"nctId":2737,"briefTitle":2738,"status":697,"phases":2739,"primaryCompletion":1238,"completion":1238,"start":1291,"enrollment":1196,"conditions":2740,"interventions":2741},"NCT01921868","An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia",[90],[1208],[2722],{"intervention":2743,"totalTrials":93,"cells":2744},"NutraStem Active",{"EARLY_PHASE1":2745,"PHASE1":2747,"PHASE2":2749,"PHASE3":2751,"PHASE4":2753,"NA":2755},{"trials":2746,"activeCount":97},[],{"trials":2748,"activeCount":97},[],{"trials":2750,"activeCount":97},[],{"trials":2752,"activeCount":97},[],{"trials":2754,"activeCount":97},[],{"trials":2756,"activeCount":97},[2757],{"nctId":2758,"briefTitle":2759,"status":359,"phases":2760,"primaryCompletion":2761,"completion":2761,"start":2762,"enrollment":405,"conditions":2763,"interventions":2765},"NCT02134756","Impact of Nutritional Supplementation on Aerobic Performance and Fatigue",[90],"2015-05","2014-05",[2764,1739],"Performance",[2743,2766],"NutraStem Placebo",{"intervention":2766,"totalTrials":93,"cells":2768},{"EARLY_PHASE1":2769,"PHASE1":2771,"PHASE2":2773,"PHASE3":2775,"PHASE4":2777,"NA":2779},{"trials":2770,"activeCount":97},[],{"trials":2772,"activeCount":97},[],{"trials":2774,"activeCount":97},[],{"trials":2776,"activeCount":97},[],{"trials":2778,"activeCount":97},[],{"trials":2780,"activeCount":97},[2781],{"nctId":2758,"briefTitle":2759,"status":359,"phases":2782,"primaryCompletion":2761,"completion":2761,"start":2762,"enrollment":405,"conditions":2783,"interventions":2784},[90],[2764,1739],[2743,2766],{"intervention":2786,"totalTrials":93,"cells":2787},"Ocrelizumab",{"EARLY_PHASE1":2788,"PHASE1":2790,"PHASE2":2792,"PHASE3":2794,"PHASE4":2796,"NA":2798},{"trials":2789,"activeCount":97},[],{"trials":2791,"activeCount":97},[],{"trials":2793,"activeCount":97},[],{"trials":2795,"activeCount":97},[],{"trials":2797,"activeCount":97},[],{"trials":2799,"activeCount":97},[2800],{"nctId":2801,"briefTitle":2802,"status":359,"phases":2803,"primaryCompletion":2804,"completion":2804,"start":2805,"enrollment":11,"conditions":2806,"interventions":2814},"NCT03562975","Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus",[],"2023-01-11","2018-07-23",[30,2807,2808,2809,2810,2811,2812,2813],"Pathologic Processes","Demyelinating Diseases","Nervous System Diseases","Autoimmune Diseases","Immune System Diseases","Primary Progressive Multiple Sclerosis","Relapsing Remitting Multiple Sclerosis",[2786],{"intervention":2816,"totalTrials":93,"cells":2817},"minocycline",{"EARLY_PHASE1":2818,"PHASE1":2820,"PHASE2":2822,"PHASE3":2824,"PHASE4":2826,"NA":2828},{"trials":2819,"activeCount":97},[],{"trials":2821,"activeCount":97},[],{"trials":2823,"activeCount":97},[],{"trials":2825,"activeCount":97},[],{"trials":2827,"activeCount":97},[],{"trials":2829,"activeCount":97},[2830],{"nctId":2831,"briefTitle":2832,"status":359,"phases":2833,"primaryCompletion":922,"completion":2834,"start":2835,"enrollment":2836,"conditions":2837,"interventions":2839},"NCT01531582","Minocycline in the Treatment of Angelman Syndrome",[90],"2015-09","2012-04",25,[2838],"Angelman Syndrome",[2816],{"intervention":2841,"totalTrials":93,"cells":2842},"dust mite extract or placebo",{"EARLY_PHASE1":2843,"PHASE1":2845,"PHASE2":2847,"PHASE3":2849,"PHASE4":2851,"NA":2853},{"trials":2844,"activeCount":97},[],{"trials":2846,"activeCount":97},[],{"trials":2848,"activeCount":97},[],{"trials":2850,"activeCount":97},[],{"trials":2852,"activeCount":97},[],{"trials":2854,"activeCount":97},[2855],{"nctId":2856,"briefTitle":2857,"status":359,"phases":2858,"primaryCompletion":1735,"completion":1735,"start":1773,"enrollment":202,"conditions":2859,"interventions":2861},"NCT01179282","Repeated Nasal Challenge in Skin Prick-puncture Negative and Intradermal Positive Dust Mite Allergic Rhinitis Patients",[90],[2860],"ALLERGIC RHINITIS",[2841],{"intervention":2863,"totalTrials":93,"cells":2864},"Switch NRTIs as a Backbone to Raltegravir",{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2869,"PHASE3":2871,"PHASE4":2873,"NA":2875},{"trials":2866,"activeCount":97},[],{"trials":2868,"activeCount":97},[],{"trials":2870,"activeCount":97},[],{"trials":2872,"activeCount":97},[],{"trials":2874,"activeCount":97},[],{"trials":2876,"activeCount":97},[2877],{"nctId":2878,"briefTitle":2879,"status":359,"phases":2880,"primaryCompletion":2881,"completion":2881,"start":2882,"enrollment":2883,"conditions":2884,"interventions":2887},"NCT00749580","A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen",[90],"2011-07","2008-11",46,[2885,2886],"Virus Diseases","HIV",[2863],{"intervention":2889,"totalTrials":93,"cells":2890},"gentamyacin",{"EARLY_PHASE1":2891,"PHASE1":2893,"PHASE2":2895,"PHASE3":2897,"PHASE4":2899,"NA":2901},{"trials":2892,"activeCount":97},[],{"trials":2894,"activeCount":97},[],{"trials":2896,"activeCount":97},[],{"trials":2898,"activeCount":97},[],{"trials":2900,"activeCount":97},[],{"trials":2902,"activeCount":97},[2903],{"nctId":2904,"briefTitle":2905,"status":547,"phases":2906,"primaryCompletion":539,"completion":539,"start":2907,"enrollment":97,"conditions":2908,"interventions":2910},"NCT00669799","Topical Antibiotic Use In Chronic Rhinosinusitis A Double-Blinded, Randomized, Placebo Controlled Study",[90],"2008-03",[2909],"Rhinosinusitis",[2889,2889],{"intervention":2912,"totalTrials":93,"cells":2913},"Zostavax®",{"EARLY_PHASE1":2914,"PHASE1":2916,"PHASE2":2918,"PHASE3":2920,"PHASE4":2922,"NA":2924},{"trials":2915,"activeCount":97},[],{"trials":2917,"activeCount":97},[],{"trials":2919,"activeCount":97},[],{"trials":2921,"activeCount":97},[],{"trials":2923,"activeCount":97},[],{"trials":2925,"activeCount":97},[2926],{"nctId":2927,"briefTitle":2928,"status":198,"phases":2929,"primaryCompletion":2930,"completion":2930,"start":1961,"enrollment":173,"conditions":2931,"interventions":2935},"NCT02960399","Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older",[90],"2017-12",[2932,2933,2934],"Common Variable Immune Deficiency","Specific Antibody Deficiency","X-linked Agammaglobulinemia",[2912]]